Jacob Rubens, Quotient Therapeutics CEO
August 28, 2024 06:30 AM EDT
Startups
Deals
R&D

Pfiz­er part­ners with Flag­ship ge­net­ics start­up Quo­tient on heart and kid­ney drugs

Ryan Cross

Senior Science Correspondent

Pfiz­er has struck its sec­ond part­ner­ship with a Flag­ship Pi­o­neer­ing start­up, work­ing with Quo­tient Ther­a­peu­tics to iden­ti­fy ge­net­ic mu­ta­tions that arise by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times